BHC Stock Overview
Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bausch Health Companies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.11 |
| 52 Week High | US$11.46 |
| 52 Week Low | US$3.96 |
| Beta | 0.75 |
| 11 Month Change | 36.07% |
| 3 Month Change | 16.36% |
| 1 Year Change | -1.58% |
| 33 Year Change | -70.88% |
| 5 Year Change | -58.41% |
| Change since IPO | 1,522.00% |
Recent News & Updates
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%
Aug 06
Recent updates
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%
Aug 062 Red Alerts On Bausch Health Companies
Jul 25The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff
Sep 21Shareholder Returns
| BHC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.9% | -0.8% | 1.8% |
| 1Y | -1.6% | 22.3% | 31.9% |
Return vs Industry: BHC underperformed the US Pharmaceuticals industry which returned 22.3% over the past year.
Return vs Market: BHC underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| BHC volatility | |
|---|---|
| BHC Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BHC's share price has been volatile over the past 3 months.
Volatility Over Time: BHC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20,270 | Tom Appio | www.bauschhealth.com |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Bausch Health Companies Inc. Fundamentals Summary
| BHC fundamental statistics | |
|---|---|
| Market cap | US$2.95b |
| Earnings (TTM) | -US$471.00m |
| Revenue (TTM) | US$9.20b |
0.3x
P/S Ratio-6.3x
P/E RatioIs BHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHC income statement (TTM) | |
|---|---|
| Revenue | US$9.20b |
| Cost of Revenue | US$2.69b |
| Gross Profit | US$6.52b |
| Other Expenses | US$6.99b |
| Earnings | -US$471.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 70.80% |
| Net Profit Margin | -5.12% |
| Debt/Equity Ratio | -9,541.9% |
How did BHC perform over the long term?
See historical performance and comparison